ClinicalTrials.gg
CompletedNCT04704518PRO-037Updated Apr 7, 2026Results posted

Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy

A Phase 4 interventional study of Sodium Hyaluronate Ophthalmic 0.4% and Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15% in Photorefractive Keratectomy and Corneal De-epithelialization, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Laboratorios Sophia S.A de C.V. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Phase IV comparative, controlled, parallel group, open, randomized multicenter study to evaluate the efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo. Primary outcome measure is the time of corneal re-epithelialization after PRK surgery. Intervention includes administration of one of the experimental products quater per die (QID) for 14 days.

02

Conditions studied

  • Photorefractive Keratectomy
  • Corneal De-epithelialization
03

In context

Lead sponsor

Laboratorios Sophia S.A de C.V. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Age ≥ 18 and ≤ 45 years old
  • Being on PRK postoperative day 1 (right eye will be evaluated for efficacy)
  • Presenting a PRK surgical corneal ablation surface of 5.5 to 6.0 mm
  • PRK corneal output ≤ 60 µm
  • Preoperative refraction of -1.0 to -4.5 D of myopia or myopic astigmatism (in this case, the sum of both values with a spherical equivalent no greater than -4.5 D)
  • Being capable of voluntarily grant a signed .
  • Being willing and able to meet the requirements of the study such as attending programmed visits, treatment plan and other study procedures.
  • Being willing and able to modify the required lifestyle activities.
  • Women in child-bearing age must assure the continuation (start ≥ 30 days prior to informed consent signing) of a hormonal method or intrauterine device (IUD) during the study.

Exclusion criteria

Exclusion Criteria:

  • Having suffered any complications during and after PRK surgical procedure previous to inclusion in the study.
  • Use of mitomycin during PRK
  • Being subjected to PRK retreatment of previous history of any other kind of refractive surgery.
  • Pregnancy, breastfeeding or planning to become pregnant during the time of the study
  • Having participated in clinical trials within 30 days prior to signing this study's form.
  • Having participated previously in this study.
  • Diagnosis of any of the following:

    • Allergic, viral or bacterial conjunctivitis
    • Dry eye
    • Anterior blepharitis
    • Parasite infestation of ocular structures (Demodex, for example)
    • Previous history of ocular herpes
    • Previous history of ocular inflammation (such as uveitis)
    • Corneal or conjunctival ulcers
    • Glaucoma
  • Previous history of drug addiction within the last 2 years previous to signing this study's informed consent form.
  • Having a previous history of any ophthalmological surgical procedure, within the last 3 months prior to the informed consent signing date.
  • Previous history of any medical affliction, acute or chronic (such as Diabetes Mellitus type I/II, diseases or ), that according to the investigator may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results.
  • Use of medications (such as retinoic acid) that according to the investigator's criteria may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results.
  • Known to any of the components of the products used in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Group 1; Lagricel® Ofteno PF

    Lagricel® Ofteno PF, multidose presentation (sodium hyaluronate 0.4%) Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.

    Drug: Sodium Hyaluronate Ophthalmic 0.4%

  • Active comparator
    Group 2; Thealoz® Duo

    Thealoz® Duo, (trehalose 3%/sodium hyaluronate 0.15%). Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.

    Drug: Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%

Interventions

  • DrugSodium Hyaluronate Ophthalmic 0.4%

    Topical ophthalmic administration of one drop of Lagricel® Ofteno PF QID.

    Also known as: Lagricel® Ofteno PF, PRO-037

  • DrugTrehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%

    Drug page: Trehalose

    Topical ophthalmic administration of one drop of Thealoz® Duo QID.

    Also known as: Thealoz® Duo

06

What researchers measure

Primary outcomes

  1. Changes in Corneal Re-epithelialization (Time)

    Corneal re-epithelialization will be evaluated through direct observation and photographic recording after application of fluorescein stain. After instillation of a drop of topical anesthetic (tetracaine 0.5%) a fluorescein strip will be applied on the inferior cul de sac while the patient looks upward. Using a slit lamp with magnification of 6x and 16x photographs (at least 6 images for each magnification) will be obtained.

    Time frame: Days: 1 (baseline visit), 2 (±1) (first follow-up visit), 3 (±1) (second follow-up visit), 7 (±1) (third follow-up visit)

  2. Best Corrected Visual Acuity (BCVA)

    (VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.

    Time frame: Days: 1 (baseline visit: BV), 2 (±1) (first follow-up visit: V1), 3 (±1) (second follow-up visit: V2), 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)

Secondary outcomes

  1. Changes in Ocular Comfort Index

    Ocular Comfort Index (OCI) Questionnaire will be used for evaluation of tolerability through incidence and severity of dry eye symptoms in a scale from 0 to 100. Greater scores mean a worse outcome.

    Time frame: Days: 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)

  2. Pain Perception

    Through a questionnaire, patients will be directly questioned about presence and severity of pain and associated symptoms. The scale will be as follows for severity: absent (0), very mild (1), mild (2), moderate (3) and severe (4)

    Time frame: Days: 1 (baseline visit: BV), 2 (±1) (first follow-up visit: V1), 3 (±1) (second follow-up visit: V2), 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)

  3. Frequency of Pain Perception

    Through a questionnaire, patients will be directly questioned about presence, severity and frequency of pain and associated symptoms. The scale will be as follows for frequency: never (0), almost never (1), 50% of the time (2), almost all the time (3) and all the time (4).

    Time frame: Days: 1 (baseline visit: BV), 2 (±1) (first follow-up visit: V1), 3 (±1) (second follow-up visit: V2), 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)

  4. Unexpected Adverse Events (AEs) Related to the Investigational Product

    The number of unexpected adverse events related to the investigational product that were recorded in each treatment group is described

    Time frame: Day: 17 (± 1) (safety call)

07

Results

Posted Apr 7, 2026

Participant flow

Participant flow — Overall Study
MilestoneGroup 1; Lagricel® Ofteno PFGroup 2; Thealoz® Duo
Started4848
Completed4543
Not completed35
Withdrew: Protocol violation13
Withdrew: Adherence below protocol-stipulated limit (70%)22

Outcome measures

PrimaryChanges in Corneal Re-epithelialization (Time)

Corneal re-epithelialization will be evaluated through direct observation and photographic recording after application of fluorescein stain. After instillation of a drop of topical anesthetic (tetracaine 0.5%) a fluorescein strip will be applied on the inferior cul de sac while the patient looks upward. Using a slit lamp with magnification of 6x and 16x photographs (at least 6 images for each magnification) will be obtained.

Time frame:
Days: 1 (baseline visit), 2 (±1) (first follow-up visit), 3 (±1) (second follow-up visit), 7 (±1) (third follow-up visit)
Reported as:
Mean · days
Changes in Corneal Re-epithelialization (Time)
daysGroup 1; Lagricel® Ofteno PFGroup 2; Thealoz® Duo
Changes in Corneal Re-epithelialization (Time)5.39 ± 3.785.34 ± 3.46
PrimaryBest Corrected Visual Acuity (BCVA)

(VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.

Time frame:
Days: 1 (baseline visit: BV), 2 (±1) (first follow-up visit: V1), 3 (±1) (second follow-up visit: V2), 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)
Reported as:
Mean · decimal score
Best Corrected Visual Acuity (BCVA)
decimal scoreGroup 1; Lagricel® Ofteno PFGroup 2; Thealoz® Duo
BV0.58 ± 0.160.61 ± 0.20
V10.53 ± 0.160.55 ± 0.15
V20.62 ± 0.180.65 ± 0.20
V30.80 ± 0.180.76 ± 0.22
FV0.88 ± 0.180.86 ± 0.19
SecondaryChanges in Ocular Comfort Index

Ocular Comfort Index (OCI) Questionnaire will be used for evaluation of tolerability through incidence and severity of dry eye symptoms in a scale from 0 to 100. Greater scores mean a worse outcome.

Time frame:
Days: 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)
Reported as:
Mean · score on a scale
Changes in Ocular Comfort Index
score on a scaleGroup 1; Lagricel® Ofteno PFGroup 2; Thealoz® Duo
V325.20 ± 11.8825.25 ± 11.36
FV20.32 ± 11.7819.51 ± 12.68
SecondaryPain Perception

Through a questionnaire, patients will be directly questioned about presence and severity of pain and associated symptoms. The scale will be as follows for severity: absent (0), very mild (1), mild (2), moderate (3) and severe (4)

Time frame:
Days: 1 (baseline visit: BV), 2 (±1) (first follow-up visit: V1), 3 (±1) (second follow-up visit: V2), 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)
Reported as:
Count of participants · Participants
Pain Perception
ParticipantsGroup 1; Lagricel® Ofteno PFGroup 2; Thealoz® Duo
BV Pain Perception — No pain33
BV Pain Perception — Very mild pain47
BV Pain Perception — Mild pain811
BV Pain Perception — Moderate mild2318
BV Pain Perception — Severe pain74
V1 Pain Perception — No pain76
V1 Pain Perception — Very mild pain96
V1 Pain Perception — Mild pain1317
V1 Pain Perception — Moderate mild1512
V1 Pain Perception — Severe pain12
V2 Pain Perception — No pain2321
V2 Pain Perception — Very mild pain129
V2 Pain Perception — Mild pain812
V2 Pain Perception — Moderate mild10
V2 Pain Perception — Severe pain11
V3 Pain Perception — No pain3836
V3 Pain Perception — Very mild pain74
V3 Pain Perception — Mild pain01
V3 Pain Perception — Moderate mild02
V3 Pain Perception — Severe pain00
FV Pain Perception — No pain4441
FV Pain Perception — Very mild pain01
FV Pain Perception — Mild pain10
FV Pain Perception — Moderate mild01
FV Pain Perception — Severe pain00
SecondaryFrequency of Pain Perception

Through a questionnaire, patients will be directly questioned about presence, severity and frequency of pain and associated symptoms. The scale will be as follows for frequency: never (0), almost never (1), 50% of the time (2), almost all the time (3) and all the time (4).

Time frame:
Days: 1 (baseline visit: BV), 2 (±1) (first follow-up visit: V1), 3 (±1) (second follow-up visit: V2), 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)
Reported as:
Count of participants · Participants
Frequency of Pain Perception
ParticipantsGroup 1; Lagricel® Ofteno PFGroup 2; Thealoz® Duo
BV Frequency pain perception — At no time33
BV Frequency pain perception — Almost never129
BV Frequency pain perception — 50% of the time910
BV Frequency pain perception — Almost all the time1516
BV Frequency pain perception — At all times65
V1 Frequency pain perception — At no time76
V1 Frequency pain perception — Almost never1411
V1 Frequency pain perception — 50% of the time1516
V1 Frequency pain perception — Almost all the time97
V1 Frequency pain perception — At all times03
V2 Frequency pain perception — At no time2321
V2 Frequency pain perception — Almost never1817
V2 Frequency pain perception — 50% of the time32
V2 Frequency pain perception — Almost all the time11
V2 Frequency pain perception — At all times02
V3 Frequency pain perception — At no time3836
V3 Frequency pain perception — Almost never76
V3 Frequency pain perception — 50% of the time00
V3 Frequency pain perception — Almost all the time00
V3 Frequency pain perception — At all times01
FV Frequency pain perception — At no time4441
FV Frequency pain perception — Almost never11
FV Frequency pain perception — 50% of the time00
FV Frequency pain perception — Almost all the time00
FV Frequency pain perception — At all times01
SecondaryUnexpected Adverse Events (AEs) Related to the Investigational Product

The number of unexpected adverse events related to the investigational product that were recorded in each treatment group is described

Time frame:
Day: 17 (± 1) (safety call)
Reported as:
Number · number of events
Unexpected Adverse Events (AEs) Related to the Investigational Product
number of eventsGroup 1; Lagricel® Ofteno PFGroup 2; Thealoz® Duo
expected related adverse events1712
Unexpected adverse events related to21

Adverse events

Collected over From day 1 (basal visit) to the safety call on day 17 (+1). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1; Lagricel® Ofteno PF0/48 (0%)0/48 (0%)39/48 (81.3%)
Group 2; Thealoz® Duo0/47 (0%)0/47 (0%)37/47 (78.7%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventGroup 1; Lagricel® Ofteno PFGroup 2; Thealoz® Duo
Corneal epithelial defectEye disorders22/4821/47
Eye irritationEye disorders6/489/47
Irritation in the instillation areaEye disorders9/485/47
Foreign body sensation in the eyesEye disorders9/486/47
Dry eyeEye disorders3/487/47
Decreased visual acuityEye disorders4/485/47
PhotophobiaEye disorders5/482/47
Blurred visionEye disorders5/481/47
Abnormal sensation in the eyeEye disorders4/481/47
Eyelid edemaEye disorders2/483/47

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1; Lagricel® Ofteno PFGroup 2; Thealoz® DuoTotal
Mean29.50 ± 7.0126.74 ± 5.7528.14 ± 6.53
Sex: Female, Male
Sex: Female, Male(Participants)Group 1; Lagricel® Ofteno PFGroup 2; Thealoz® DuoTotal
Female322961
Male161834
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1; Lagricel® Ofteno PFGroup 2; Thealoz® DuoTotal
Hispanic or Latin484795
Not Hispanic or Latin000
Unknown000
Region of Enrollment
Region of Enrollment(Participants)Group 1; Lagricel® Ofteno PFGroup 2; Thealoz® DuoTotal
Mexico484795
Corneal epithelial defects
Corneal epithelial defects(Participants)Group 1; Lagricel® Ofteno PFGroup 2; Thealoz® DuoTotal
Count of participants222143
08

Study locations

1 site
  • Aris Vision Institute de Guadalajara, S. C.
    Guadalajara, Jalisco, Mexico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Dec 2023, 15 months.

Results were first posted in Apr 2026, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2021
First posted
Jan 11, 2021
StartActual
Sep 3, 2022
Primary completionActual
Dec 22, 2023
CompletionActual
Dec 22, 2023
Results first posted
Apr 7, 2026
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04704518
Responsible party
Sponsor
First posted
Jan 11, 2021
Start date
Sep 3, 2022
Primary completion
Dec 22, 2023
Completion
Dec 22, 2023
Results posted
Apr 7, 2026
Last update
Apr 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion